TSH Biopharm Corporation Limited (TPEX:8432)
Taiwan · Delayed Price · Currency is TWD 55.70
+0.30 (0.54%)
Jan 22, 2026, 1:30 PM CST
TSH Biopharm Corporation Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,270 | 1,116 | 810.92 | 741.07 | 413.48 | 447.86 | Upgrade | |
Revenue Growth (YoY) | 20.85% | 37.59% | 9.43% | 79.22% | -7.68% | -11.78% | Upgrade |
Cost of Revenue | 623.17 | 532.95 | 411.02 | 351.2 | 166.13 | 162.67 | Upgrade |
Gross Profit | 646.93 | 582.76 | 399.9 | 389.87 | 247.36 | 285.19 | Upgrade |
Selling, General & Admin | 419.11 | 384.16 | 313.39 | 289.71 | 168.33 | 182.31 | Upgrade |
Research & Development | 23.71 | 27.99 | 24.81 | 31.09 | 23.52 | 28.68 | Upgrade |
Operating Expenses | 443.12 | 412.91 | 336.27 | 323.85 | 191.74 | 210.89 | Upgrade |
Operating Income | 203.81 | 169.86 | 63.63 | 66.03 | 55.62 | 74.3 | Upgrade |
Interest Expense | -0.74 | -0.46 | -0.69 | -0.7 | -0.08 | -0.03 | Upgrade |
Interest & Investment Income | 14.68 | 11.98 | 13.06 | 9.71 | 8.46 | 8.66 | Upgrade |
Currency Exchange Gain (Loss) | -0.38 | 0.33 | -0.43 | 6.39 | -1.26 | 0.41 | Upgrade |
Other Non Operating Income (Expenses) | 1.2 | 1.39 | 0.56 | -0.13 | -1.23 | -4.55 | Upgrade |
EBT Excluding Unusual Items | 218.57 | 183.1 | 76.13 | 81.3 | 61.51 | 78.79 | Upgrade |
Gain (Loss) on Sale of Investments | 1.11 | - | - | - | - | -1.56 | Upgrade |
Gain (Loss) on Sale of Assets | -0.68 | -0.87 | -0.04 | -0.06 | -0 | - | Upgrade |
Asset Writedown | -8.8 | -8.8 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | 0.05 | - | Upgrade |
Pretax Income | 210.2 | 173.43 | 76.09 | 81.24 | 61.55 | 77.23 | Upgrade |
Income Tax Expense | 49.89 | 39.29 | 11.11 | 15.1 | 14.44 | 15.66 | Upgrade |
Earnings From Continuing Operations | 160.32 | 134.15 | 64.98 | 66.14 | 47.11 | 61.57 | Upgrade |
Minority Interest in Earnings | -35.3 | -21.06 | -2.99 | -4.25 | - | - | Upgrade |
Net Income | 125.02 | 113.09 | 61.99 | 61.89 | 47.11 | 61.57 | Upgrade |
Net Income to Common | 125.02 | 113.09 | 61.99 | 61.89 | 47.11 | 61.57 | Upgrade |
Net Income Growth | 4.46% | 82.44% | 0.16% | 31.38% | -23.49% | -27.84% | Upgrade |
Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 | 38 | Upgrade |
Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 | 38 | Upgrade |
Shares Change (YoY) | 0.05% | 0.04% | -0.05% | 0.05% | 0.01% | - | Upgrade |
EPS (Basic) | 3.26 | 2.95 | 1.61 | 1.61 | 1.23 | 1.60 | Upgrade |
EPS (Diluted) | 3.25 | 2.94 | 1.61 | 1.61 | 1.23 | 1.60 | Upgrade |
EPS Growth | 4.51% | 82.61% | - | 31.23% | -23.32% | -27.93% | Upgrade |
Free Cash Flow | 171.9 | 182.04 | 28.49 | 30.62 | 68.33 | 9.7 | Upgrade |
Free Cash Flow Per Share | 4.47 | 4.74 | 0.74 | 0.80 | 1.78 | 0.25 | Upgrade |
Dividend Per Share | 2.120 | 2.120 | 1.280 | 1.600 | 1.500 | 1.800 | Upgrade |
Dividend Growth | 65.63% | 65.63% | -20.00% | 6.67% | -16.67% | - | Upgrade |
Gross Margin | 50.93% | 52.23% | 49.31% | 52.61% | 59.82% | 63.68% | Upgrade |
Operating Margin | 16.05% | 15.22% | 7.85% | 8.91% | 13.45% | 16.59% | Upgrade |
Profit Margin | 9.84% | 10.14% | 7.64% | 8.35% | 11.39% | 13.75% | Upgrade |
Free Cash Flow Margin | 13.53% | 16.32% | 3.51% | 4.13% | 16.52% | 2.17% | Upgrade |
EBITDA | 210.5 | 185.11 | 77.65 | 79.28 | 60.87 | 79.66 | Upgrade |
EBITDA Margin | 16.57% | 16.59% | 9.58% | 10.70% | 14.72% | 17.79% | Upgrade |
D&A For EBITDA | 6.69 | 15.26 | 14.02 | 13.25 | 5.26 | 5.35 | Upgrade |
EBIT | 203.81 | 169.86 | 63.63 | 66.03 | 55.62 | 74.3 | Upgrade |
EBIT Margin | 16.05% | 15.22% | 7.85% | 8.91% | 13.45% | 16.59% | Upgrade |
Effective Tax Rate | 23.73% | 22.65% | 14.61% | 18.58% | 23.46% | 20.28% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.